CLINICAL & PIPELINE·Clinical Trial Completion
Retina Research Foundation Completes Phase I/II Study for Ranibizumab (Lucentis) in Macular Degeneration
Retina Research Foundation completed a Phase I/II study (NCT00467935) for ranibizumab (Lucentis) in advanced wet Macular Degeneration. This trial investigated scotoma reduction and improved visual function in 20 patients, concluding in November 2007. The findings contribute to the understanding of anti-VEGF therapies for AMD, informing future R&D strategies and procurement decisions for ophthalmic treatments, highlighting ongoing innovation in this critical therapeutic area.
90-Day Activity